THERAPEUTIC POTENTIAL OF ALPINIA GALANGA: A COMPREHENSIVE REVIEW OF PHARMACOLOGICAL ACTIVITES

Avijit Bej*, Dr. Vikas Kumar Singh*, Zannatul Firdous, Anuj Kumar, Govinda Kumar, Suraj Kumar, Vicky Kumar, Ritesh Kumar Singh

Alpinia galanga (L.) willd., commonly known as greater galangal, is a prominent rhizomatous herb belonging to the Zingiberaceae family with a rich history of integration into traditional medical systems, including Ayurveda, Unani, and Traditional Chinese Medicine. While historically revered for managing gastrointestinal distress, respiratory ailments, rheumatic pain, and metabolic weakness, modern phytochemical and pharmacological screening has unveiled a complex matrix of bioactive secondary metabolites that validate and expand upon these ethnobotanical claims. This comprehensive review synthesizes the current scientific understanding of Alpinia galanga, focusing on its primary pharmacophores—most notably 1'S-1'-acetoxychavicol acetate (ACA), galangin, eugenol, and 1,8-cineole. Extensive in vitro and in vivo investigations demonstrate a robust spectrum of therapeutic activities, encompassing potent broad-spectrum antimicrobial, antiviral, and antifungal properties, alongside profound anti-inflammatory and free-radical scavenging capabilities that actively mitigate cellular oxidative stress. Furthermore, the review details emerging evidence of its specialized pharmacological roles, notably its neuroprotective effects through acetylcholinesterase inhibition and protection against amyloid-induced cognitive decline, its gastroprotective and nephroprotective tissue defense mechanisms, and its notable anticancer and chemo-preventive potential driven by apoptosis induction and the modulation of detoxification enzymes. Additionally, recent studies highlight its metabolic benefits, demonstrating promising anti-diabetic, hypolipidemic, and immunomodulatory effects. While emphasizing the plant's generally favorable safety profile and its immense potential as a foundational source for functional therapeutics, this review also addresses critical contemporary translational challenges. Specifically, it highlights the poor systemic bioavailability of its key flavonoid constituents and emphasizes the urgent necessity for advanced drug delivery systems such as nanoemulsions and phytosomes coupled with rigorous, double-blind human clinical trials to seamlessly transition Alpinia galanga from a traditional herbal remedy into a standardized, evidence-based modern pharmacotherapy.